Title of Invention

AN AQUEOUS COMPOSITION COMPRISING ALKYL PYRROLIDONE AND ALKYL POLYSACCHARIDE

Abstract invention relates to an aqueous composition comprising an alkyl pyrrolidone, such as a C8-C18 linear alkyl pyrrolidone, and an alkyl polysaccharide such as an alkyl polyglucoside, and a method of enhancing the efficacy of an enzyme containing composition for use in cleaning medical instruments comprising the step of including in said composition an alkyl pyrrolidone and an alkyl polysaccharide. The methods and compositions of the present invention may further include at least one enzyme such as proteases, hpases amylases and cellulases
Full Text 1-
SURFACTANT SYSTEM
TECHNICAL FIELD
The invention relates to a surfactant system for use id aqueous composition 2nd more particularly to a surfactant system for use in, or addition to, aqueous enzyme based cleaning preparations. The invention has particular advantage when employed in enzyme based cleaning preparations intended for use for cleaning medical instruments. BACKGROUND ART
Any discussion of the prior art throughout the specification should in no way be considered as an admission that such prior art is widely known or forms part of common general knowledge in the field.
The invention is herein described with particular reference to compositions for cleaning medical instruments, but is not limited to that use. As herein used the term "medical instruments" is intended broadly to include surgical such as calpels, biopsy Instruments, clamps, and the likes; endoscopes, colonoscopes, laparoseepes and other paraphernalia used for surgical investigation or intcrvention; and other instruments used in the practice of medicine, surgery, and dentistry which require cleaning, disinfection or sterilisation. The term is also intended to include instruments having similar cleaning requirements such as those used in hairdressing, cosmetic treatments, tattooing, body piercing etc as well as offer applications where removal of human/animal sebum and/or body secretion is required. Many medical instruments are

wO 02/18530 PCT/AU01/01094
-2-
made from or incorporate a variety of construction materials and cleaning compositions must be such as not to attack any such materials.
It is common practice to clean medical instruments after use with one patient and prior to treatment of another by scrubbing to remove blood, tissue, loose proteinatious and other soils, and then soaking for a predetermined period in an enzyme preparation adapted to further digest or loosen any proteinacious materials remaining on the instrument surface The instruments are then rinsed clean and subjected to further disinfection or sterilization procedures. To minimize the possibility of cross infection instruments used with one patient are desirably cleaned separately from those used with another.
Preparations for use in cleaning medical instruments consist generally of a concentrate comprising one or more surfactants in combination with one or more proteolytic enzymes. The concentrate is diluted to a working strength (normally a hundredfold dilution) prior to use. One such formulation has been described by NOVO NORDISK ("Novo-formulation").-Three preparations used internationally for this purpose are EPIZYME ® a product of 3M, MEDIZYME ® (a product of Whiteley Industries Pty Ltd., Sydney Australia) and ENDOZYME ® (a product of Ruholf Corporation, NY, USA). While such products are generally effective and widely used there remains a need for prodncts which are more efficient, and especially for preparations which are capable of achieving a predetermined level of effectiveness within a shorter time than those currently available.
The concentrate must be sufficiently stable in transit and storage prior to use to satisfy the needs of commerce. The choice of surfactants which in practice can be formulated in concentrated aqueous solutions is limited. Either the surfactants limit the storage stability of the concentrate, resulting in problems of foaming on dilution, provide insufficient reduction in surface tension, destabilize other components of the system such as enzymes, or suffer from other disadvantages. Mostly, formulators utilize surfactants chosen from a small group of conventional and well known nonionic surfactants which have been found to be satisfactory for such uses, but there remains an unsatisfied demand for formulations of improved efficiency.
It is an object of the invention to provide an improved surfactant system and of preferred embodiments cf the invention TO Provide an crzyme based cleaning

composition which avoids problems of the prior art and/or provides improved performance.
SUMMARY
An aqueous composition comprising composition being a surfactant system comprising an alkyl pyrrolidone and an alkyl polysaccharide in the ratio of 1:37.5 to 75:1 by weight.
DESCRIPTION OF THE INVENTION
According to a first aspect the invention provides an aqueous composition comprising in combination an alkyl pyrrolidone and an alkyl polysaccharide.
For preference the alkyl pyrrolidone is a C8-C18 linear alkyl pyrrolidone. N- dodecyl pyrrolidone ("N-DP") is highly preferred. Desirably, the alkyl polysaccharide is an alkyl polyglucoside ("APG")-
According to a second aspect the invention provides a method of enhancing the efficacy of an enzyme containing composition for use in cleaning medical instruments comprising the step of including an alkyl pyrrolidone and an alkyl polysaccharide.
Preferably the composition is a concentrate which contains surfactant according to the first aspect as part of its formulation, but the surfactant system can be added subsequently either to the concentrate or the working solution.
According to a third aspect the invention provides a method of cleaning a medical instrument including the step of treating the instrument with a composition including at least one enzyme, an alkyl pyrrolidone and an alkyl polysaccharide.
Unless the context clearly requires otherwise, throughout the description and the claims, the words 'comprise', 'comprising', and the like are to be construed in an inclusive sense as opposed to an exclusive or exhaustive sense; that is to say, in the sense of "including, but not limited to".
Alkyl pyrrolidones are known to reduce surface tension progressively with increasing concentration in water achieving a minimum surface tension (maximum effectiveness) at a concentration of about 0.1% in the case of dodecyl pyrrolidone and about 0.002% in the case of octyl pyrrolidone, which concentrations correspond to the maximum solubility of the respective pyrrolidones in water. This has in the past inhibited their use in concentrates, since the maximum concentration in an aqueous system is inevitably less than fully effective as a surfactant when diluted to any substantial degree.
BEST MODES FOR CARRYING OUT THE INVENTION
An additive according to the invention consisting of n-dodecyl pyrrolidone ("n- DP") in combination with alkyl polyglucoside ("APG") was added to solutions prepared from each of three commercially available enzyme cleaning preparation concentrates.

-4-
ThesewereMEDIZYME®,ENDOZYME® and EPIZYME®. A fourth concentrate irNOVO formulation11, a product described by NOVO INDUSTRIES in Novo Nordisk Publications Application Sheet B-613, "Application of Enzymes in Detergents for Endoscope Cleaning", was also prepared and tested. In the tests described in Table 1 the additive consisted of 0.2%w/w n-dodecyl pyrrolidone ("n-DP") and 0.1%w/w of alkyl polyglucoside ("APG") in each case based on the weight of the concentrate.
The NOVO Formulation (Concentrate) is as follows:

Component %w/w
Non-ionic surfactant (Teric BL9) 12
Propylene Glycol 22
Triethanolamine 7
Boric acid 4
Calcium Chloride 0.1
Savinase 16.0L (Protease) 13
Termamyl (Amylase) 7
Water to 100
pH 7
The Epizyme composition (concentrate) is as follows:

Component %w/w
Tap water 19.0
Teric BL9 (non ionic Gurfactant) 10.0
Preservative 0.15
Enzyme stabilizer 6.0
5G% caustic soda 2.5
Propylene Glycol 6.0
Protease 10.0
Lip as e 0.2
Amylase 1.5
Cellulase 0.5
Perfume 0.15
Water to 1-00.0

WO 02/18530

PCT/AU01/01094

-5-
By way of example the protease may be subtilisin, the amylase Alpha-amylase, the cellulase may be endo-1,4-beta-glucanase and the lipase may be Triacylglycerol. However, other enzymes or combinations of enzymes may be substituted for these.
Each of the cleaning composition concentrates were diluted at a rate of 1 part of concentrate in 100 parts of standard hard water (0.304 g calcium chloride and 0.065g of magnesium chloride per 1L of distilled water. Therapeutic Goods Order 54 & Guidelines, 1996, p. 17). The efficacy of each product was then tested against standard soil preparations on glass slides, (1) neat and (2) with, the addition of an additive according to the invention. The efficiency of the preparation (time required to achieve a given score) was measured at various temperatures. The results are shown in Table 1 in comparison with results of compositions including the additive according to the invention.
Accelerated aging tests are summarized in Table 2, Details of the preparation of standard soils is given in table 3.and "Method forAscertaining the Cleaning Performance ofDishwasherDetergents"(SOPW Journal 126. Jahrgaog 3-2000)
TABLE1
Soil carrier glass microscope slides
Burnt minced meat. Contact time (min) required to achieve score E,

MGVO formulation EPIZYME MEDIZYMB ENDGZYME
Neat With APGn-DP neat Wita APG+n-DP neat With APG+ n-DP neat With APG+E-DP
25 °C 95 68 67 47 120 93 480 241
40 "C 60 46 52 37 87 71 212 157
50 "C 42 33 30 19 65 53 170 140

WO 02/18530

PCT/AUOI/01094

-6-

Milk in microwave. Contact time (in min) required to achieve score 10 [full removal)
NOVO-formulation EPIZYME MEDIZYME ENDOZYME
Neat With APG + n-DP neat With APG+n-DP neat With APG + n-DP neat With APG + n-DP
25 °C 53 38 35 25 39 30 69 51
40 °C 39 31 24 19 29 23 50 35
50 °C 27 22 12 10 19 16 31 28
Edinburgh Soil. Contact time (in min) required to achieve score 10 (full removal)
NOVO-formulation EPIZYKE MEDIZYME ENDOZYME
neat With APG + n-DP neat With APG+n-DP neat With APG + n-DP neat With APG+ n-DP
25 °C 28 25 21 19 26 23 32 28 ,
40 °C 20- - IV 10 17 11.5 25 35
50 °C 18 15 9 9 11 10 18 16
N-DP: N-dodecyl pyrrolidone (Surfadone LP 300 from International Speciality
Products),
APG: Alkyl polyglucoside (ALKADET 15 from Huntsman Corporation Australia)
Addition rate: 0.2 w/w% N-DP and 0.1 w/w% APG to concentrate
Dilution rate: 1 part of concentrate in 100 parts of standard hard water
As is evident from Table 1, the addition of the additive reduces the time required for the composition to achieve a given score and does so at each temperature. The additive is especially effective at lower temperatures.
Although the results shown in Table 1 were obtained using 0,2 w/w% N-DP and 0. lw/w% APG to concentrate, the ratio of N-DP to APG can be varied. It is preferred that the ratio be between 1 part by weight of alkyl pyrrolidone to 3 parts by weight of alkyl polyglucoside and 3 parts by weight of aDcyl pyrrolidone to 1 part by weight of alkyl polyglucoside, more preferably between 3 parts by weight of alkyl pyrrolidone to 1 parts by weight of alky! polyglucoside and 1 part by weight of alkyl pyrrolidonc to 1 pan.


WO 02/18530

PCT/AU01/01094

-7-
The concentration of N-DP and APG is each preferably less than 7.5% w/w of the concentrate (ie less than about .0075%in the concentrate at dilution of lpart concentrate: 100 parts water) and more preferably is less than 3% w/w. The actual concentrations employed will depend on the surface tension properties required, the . hydrophilicity of the alkyl polyglucosides and the degree of hydrotroping provided by other excipients in the formulation to the alkyl polyglucoside, as well as other factors which may occur with respect to individual formulations.
Table 2 shows the effect of the additive in accelerated aging tests. The results demonstrate that the additive slightly improves storage stability, or, at least, does not adversely affect it.
TABLE 2
Remaining Protease Activity in % for concentrated formulations after 21 days storage (100% at day 0):

NOVO-formulation EPIZYME MEDIZYME ENDOZYME
neat With APG + n-DP neat With APG + n-DP neat With APG + n-DP neat With APG + n-DP
25 °C 95 95 96 98 95 95 93 93
40 °C 89 89 91 91 85 85 80 83
47 °C 77 84 85 87 69 74 73 78
Assessed using B 863b test method by NOVO NORDISK (attached herewith as Annexure 1) The additive according to the invention and dilution were as for table 1.
Table 3 shows the effects of varying the concentration and ratio of the alkylpyrrolidone and alkylpolyglucoside. It can be seen that the composition is efficacious in reducing contact times for cleaning over a wide range of alkylpyrroline alkylpolyglucoside ratios.

WO 02/18530

PCT/AU01/01094

-8-
TABLE3
Soil carrier: glass microscope slides
Burnt minced meat. Contact time (min) required to achieve sccre 8.

NOVO-formulation Epizyme
neat WithAPG + SURF Neat WithAPG + SURF
25 °C 95 66 67 48
40 °C 60 49 52 39
50 °C 42 32 30 22


NOVO-formulation Epizyme
neat With APG + SURF Neat With APG+ SURF
25 °C 53 34 35 21
40 °C 39 29 24 17
50 °C 27 20 12 8
Edinburgh Soil. Contact time (in min) required to achieve score 10 (full removal)

NOVO-formulation Epizyme
neat With APG+SURF neat With APG + SURF
25 °C 28 22 21 19
40 °C 21 16 11 9
50 °C 18 19 9 8
SURF: n-dodecyl pyrrolidone (Surfadone LP 300 from International Speciality 10 Products),
APG: Alkyl polyglucoside (ALKADET 15 from Huntsman Corporation Australia)
Addition rate: 0-2 w/w% SURF and 1% APG to concentrate Dilution rate: 1 part of concentrate in 100 parts of standard hard water

WO 02/18530
-9-
Results.
Soil carrier: glass microscope slides
Burnt minced meat. Contact time (min) required to achieve score 8.

PCT/AU01/01094


NOVO-formulation Epizyme
neat With APG+SURF neat With APG+ SURF
25 °C 95 64 67 44
40 °C 60 47 52 37
50 °C 42 31 30 22
Milk in microwave. Contact time (in min) required to achieve score 10 (full removal)

NOVO-formulation ' Epizyme
neat With APG+SURF neat With APG+ SURF
25 °C 53 34 35 21
40 °C 39 28 24 16
50 °C 27 20 12 7
Edinburgh Soil. Contact time (in min) required to achieve score 10 (full removal)

NOVO-formulation Epizyme
neat With APG+SURF neat With APG+ SURF
25 °C 28 21 21 19
40 °C 21 15 11 9
50 °C 18 14 9 7
SURF: n-dodecyl pyrrolidone (Surfadone LP 300 from International Speciality
Products),
APG: Alkyl polyglucoside (ALKADET 15 fiom Huntsman Corporation Australia)
Addition rate: 0.2 w/w% SURF and 7.5% APG to concentrate
Dilution rate: 1 part of concentrate in 100 parts of standard hard water

WO 02/18530

PCT/AU01/01094

Results.
Soil carrier: glass microscope slides
Burnt minced meat. Contact time (min) required to achieve score 8.

NOVO-fonnulation Epizyme
neat With AFG+ SURF neat With APG+ SURF
25 °C 95 67 67 44
40 °C 60 44 52 41
50 6C 42 30 30 20
Milk in microwave. Contact time (in min) required to achieve score 10 (full removal)

NOVO-fonnulation Epizyme
neat With APG+ SURF neat With APG+SURF
25 °C 53 37 35 24
40 °C 39 26 24 15
50 °C 27 18 12 12
Edinburgh Soil. Contact time (in min) required to achieve score 10 (full removal)

NOVO-fonnulation Epizyme
neat With APG+ SURF neat With APG+SURF
25 °C 23 IS 21 19
40 °C 21 15 11 12
50 °C IS 12 9 7
SURF: n-dodecyl pyrrolidone (Surfadone LP 300 from International Speciality
Products),
APG: Alkyl polyglucoside (ALKADET 15 from Huntsman Corporation Australia)
Addition rate: 1% w/w% SURF and 0.1% APG to concentrate
Dilution rate: 1 part of concentrate in 100 parts of standard hard water

WO 02/18530

PCT/AU01/01094

-11-
Results.
Soil carrier: glass microscope slides
Burnt minced meat. Contact time (min) required to achieve score 8.

NOVO-fonnulation Epizyme
neat With APG+SURF neat With APG+SURF
25 °C 95 63 67 49
40 °C 60 52 52 37
50 °C 42 35 30 23
Milk in microwave. Contact time (in min) required to achieve score 10 (full removal)

NOVO-formulation Epizyme
neat With APG + SURF neat With APG+ SURF
25 °C 53 35 35 24-
40 °C 39 27 24 16
50 °C 27 24 12 9
Edinburgh Soil. Contact time (in min) required to achieve score 10 (full removal)

NOVO-formulation Epizyme
neat With APG +SURF neat With APG + SURF
25 °C 28 23 21 " 20
40 °C 21 17 11 9
50 °C 18 12 9 7
SURF: n-dodecyl pyrrolidone (Surfadone LP 300 from International Speciality
Products),
APG: Alkyl polyglucoside (ALKADET 15 from Huntsman Corporation Australia)
Addition rate: 7.5% w/w% SURF and 0.1% APG to concentrate
Dilution rate: 1 part of concentrate in 100 parts of standard hard water
Assessed using B 863B test method by NOVO NORDISK (attached)

-12-
TABLE4
SOIL COMPOSITION & DETERGENT ENZYME ACTIVITY TEST
Milk in Microwave: - 60 ml of milk
- 6 beakers
- a microwave set to 450 W
- an oven heater set to 80 C°
The microwave was pre-heated by placing 6 water-filled beakers in a circle on
the glass turn-table and leaving it on "high" (900 W) for 10 minutes. Then, the beakers
with water were replaced by beakers with 10 ml of milk. The milk was heated for 10
minutes at 450 W, then allowed to cool, forming a skin, and placed into an oven for 2
hours at S0°C.
Mince meat: -20 grams of beef mince
-7.5 grams of egg yolk and whites
- 8.0 gram of water
30x30 mm polar substrate (ceramic tiles)
The mince was mixed with the egg yolk and water with the use of a hand blender, lg of homogenized mixture was spooned onto 3x3 cm ceramic tiles, onto the smooth side. Then the tiles were left in an oven for 10 minutes. Edinburgh Soil - 20 g egg yolk
- 20 g water
- 0.5 g cholesterol
-3 gbeef gelatin
- 0.45 hog mucin
The beef gelatin and water were blended together and heated until the mixture obtained a homogenous consistency. Cholesterol, hog mucin and egg yolk werE bleNded ID. after gelatin was cooled to 30C. 0.1 g of soil was deposited onto surfaces of the microscope slides. The smears were made of a uniform thickness for each sat of slides; the thickness was regulated by a border of adhesive tape along each border of the smearing instrument In order to simulate the conditions of an endoscope cleaning, the slides were left to dry in open air at 20°C for 20 minutes.
"Without wishing to be bound by theory, the polysaccharide appears to stabilize the pyrrolidone, the combination being more soluble in the concentrate and resulting in substantially improved lowering of surface tension at the working dilution.

WO 02/18530 PCT/AU01/01094
-13-
Although the test results utilize n-dodecyl pyrrolidone, other alkyl pyrroUdones could be substituted therefore, and especially C8 to C18 alkyl pyrroUdones. The amount to be added can be determined by simple trial but in general increasing the concentration significantly above the levels herein employed tends to give a decreasing advantage. Similarly, other alkyl polysaccharides may be substituted for APG. For example other sugar units and derivatives of sugar units may be substituted for glucose units. Again there is an optimum concentration beyond which increasing the concentration is of relatively little benefit. While the combination of n-alkyl pyrrolidone with APG is highly preferred, beneficial effects are obtainable with at least some soils by adding it in isolation. The optimum ratio of n-DP to APG can be determined by simple trial for a given concentrate.
The combination of the invention provides an improved surfactant system which is expected to have application in many end-uses. In the field of cleaners for medical instruments, the surfactant system of the invention may be simply added to commercially available enzyme cleaning products either to the concentrate or, at an appropriate dilution to the working solution prior to use. Preferably however the additives are incorporated into a concentrate at the time of manufacture of the concentrate which is then merely diluted prior to use.
Additives according to the invention may be added to dishwashing, hand washing and other surface cleaning compositions.
Embodiments of the invention may be altered and may have other chemicals added or substituted therefore to an extent which will be apparent to those skilled in the art from the teaching hereof without departing from the inventive concept herein disclosed.

WO 02/18530 PCT/AU01/01094
-14-
ANNEXURE
NOVO NORDISK B 863b-GB
MANUAL PROCEDURE FOR DETERMINATION OF PROTEOLYTIC ACTIVITY IN ENZYME PREPARATIONS AND DETERGENTS (AZOCASEIN SUBSTRATE)
A diagrammatic representation of this method is shown in figure 1. Principle
Aprotease is allowed to hydrolyse azocasein for 30 minutes at 40°C. Undigested protein is precipitated with trichloroacetic acid and the quantity of digested product is determined by spectrophotometry. Enzyme Unit Definition
No separate unit is defined! Activity is determined relative to a standard of known activity and the result given in the same units as used for the standard. Assay Conditions
pH: 8.5 (0.2 M Tris-SO Temperature: 40°C
Substrate: 0.5% azocasein (in reaction mixture)
Reaction time: 30 minutes Apparatus
Spectrophotometer to read absorbance at 390 nm pH meter
Water bath at 40°C • 0.5°C Timer with a second hand Vortex mixer 16 • 125 mm test tubes Repeating dispenser, 5 ml capacity Small funnels and filter paper, Whatman no. 3 or equivalent

WO 02/18530 PCT/AU01/01094
-15-
Reagents
1.2.0 M Tris buffer stock solution
Dissolve 242 g trishydroxymethylamuiomethane (Sigma "Trizma Base" T-1503 or
equivalent) in 700-800 ml deionised water.
Adjust pH to 8.5 with 10 NH2SO4
Adjust volume to 1 litre.
This concentrate is to be used at 10 ml/100 ml volume for all final dilutions with 0.2 M
Tris buffer.
2. 50% urea solution
Dissolve 50 g urea (analytical grade) in 50 ml warm deionised water.
Adjust volume to 1 litre.
3.10% trichloroacetic acid solution (stop reagent)
Dissolve, 100, g trichloroacetic add (TCA) in 200rml'deiom's'ed'waier.
Adjust volume to 1 litre.
4. Azoecasein (substrate solution)
Make fresh daily - discard any unused substrate
In a 250-ml beaker:
Weigh 0.6g azocasein (Sigma A-2765).
Add 10 ml 50% urea solution and mix until dissolved.
Add 10 ml 2.0 M Tris buffer stock solution.
Add 30-50 ml deionised water and continue stirring until clear of particles.
Adjust pH to 8.5 using dilute H2SO4 Adjust volume to 100 ml and mix thoroughly.
Keep cool until ready to begin assay.
5. Enzyme samples and standards
See Appendix I for Alcalase®, Appendix II for Esperase® and Savinase®, and Appendix HI for Durazym®.
After dissolving a detergent sample for protease assay, it is strongly recommended that the pH of this solution be checked and, if needed, adjusted to 8.5 •
0.1 units.

WO 02/18530 PCT/AU01/01094
-16-
If it is desired to know the exact activity levels of proteinase in a detergent the detergent bases should be included in the standard solutions unless it is already known that the particular formulation being used has no effect on the protease activity. The concentration of the base detergent should be equal to that used in the sample solution of the detergent containing protease.
The presence in solution of strong chelators such as NTA or EDTA may result in deactivation of the protease over the time period required for preparation of the various materials for the assay. This cause of deactivation can be overcome by adding excess calcium to the sample solutions.
Procedure
1. Preheat water bath to 40°C± 0.5°C (approx. 1 hr.).
2. Approx. 10 minutes before starting assay, place substrate solution in 40°C water
bath to equilibrate.
3. To appropriately labelled test tubes, pipet 1 ml of sample or enzyme standard and
equilibrate to 40°C in water bath (approx. 1 minute).
4. Start reaction:
At precisely timed intervals, add 5 ml substrate solution to each tube containing
sample or standard, vortex and return to water bath for 30 minutes.
Sample blank:
To sample blank add 5 ml 10% TCA and vortex; then add 5 ml substrate
solution, vortex and let stand at room temperature until ready to filter.
5. Stop reaction:
After exactly 30 minutes, at the same time intervals as before, add 5 ml of 10% TCA to each sample or standard tube, vortex and let stand at room temperature
6. After 15-20 minutes filter all tubes by gravity filtration through paper filters into
clean, dry and properly -labelled test tubes.
7. Read absorbances at 390 nm vs deionised water blank.

WO 02/18530 PCT/AU01/O1094
-17-
Calculations
1. Standard curve:
a) If standard blank (A0 E0 or S0) > 0.16, assay should be re-run with fresh
substrate
b) If standard blank obtain * absorb ance
c)Plot a curve of absorbance vs proteolytic activity (AU or KNPU/tube - AU or KNPU/ml of final dilution).
2. Sample tubes:
• absorbance = Asampale - Ablank
Using standard curve, determine activity of sample/tube, Activity/gram = (activitv/tube) • (dilution factor)
gram of sample

WO 02/18530

PCT/AU01/01094

-18-
APPENDIX 1 Alcalase®
Unit definition: Anson Unit (AU)
1 Anson Unit = the amount of enzyme* which digests haemoglobin A an initial rate such that there is liberated per minute an amount of TCA-soluble product which gives the same colour with phenol reagent as one milliequivalent of tyrosine.
* Under reaction conditions given in the NNAS method AJF4/5-GB: Modified Anson— Haemoglobin Method for the Determination of Proteolytic Activity.
A standard curve is prepared using an enzyme whose activity in Anson Units is known. Unknowns are then compared to this curve.
Buffer: 0.2 M Tris, pH 8.5
Sample activity range: 5*10-5- 15*10-5 AU/ml
Standard blank: 1 ml of 0.2 M Tris buffer pH 8.5 = A0
Substrate: Azocasein solution, 0. 5%, pH 8.5
Sample preparation:
Dissolve an accurately-weighed amount of sample in an
accurately-known Volume of 0.2 M Tris buffer so that the
solution contains between 5 • 10-5 and 15 • 10-5 AU/ml and
has a pH of 8.5.
N.B. For each unknown, prepare a sample blank and one or more duplicates (as
necessary).
Keep solutions on ice until ready to assay.
Standard curve
Enzyme standard stock solution: Dissolve accurately-weighed Alcalase standard in 100
ml 0.2 M Tris buffer (pH 8.5) to yield 2.6 • 10-3 AU/ml
Dilute the stock solution as follows:

Tube 1 label Stock solution 2MTris Final volume Activity
buffer stock
A0 0ml 10ml 100 ml 0.0* 10-5 AU/ml
A1 lml 10 ml 100 ml 2.6*10-5 AU/ml
A2 2ml 10ml 100 ml 5.2*10-5 AU/ml
A3 3ml 10 ml 100 ml 7.8* 10-5 AU/ml
A4 4ml 10ml 100 ml 10.4*10-5 AU/ml
A5 5ml 10 ml 100 ml 13.0* l0-5 AU/ml
A6 6ml 10ml 100 ml 15.6*10-5AU/mJ


WO 02/38530

PCT/AU01/01094

-19-
APPENDIX II Savinase®/Espeiase®
Unit definition: Kilo Novo Protease Unit (KNPU)
1 KNPU = 1000 NIPU
1 Novo Protease Unit (NPU) = the amount of enzyme* which hydrolyzes casein at such
a rate that the initial rate of formation of peptides/minute corresponds to 1 micromole of
glycine/minute
*Standard conditions given in NNAS method 162/3-GB: Manual DMC Method for the Determination of Proteolytic Activity.
A standard curve is prepared using an enzyme whose activity in KNPU) is known. Unknowns are then compared to this curve
Buffer 0.2 MTris,pH 8.5
Sample activity range: 2*10-4- 6*10-4 KNPU/ml
Standard blank: 1 ml of 0.2 M Tris buffer pH 8.5 = E0 or So
Substrate: Azocasein solution, 0. 5%, pH 8.5
Sample preparation:
Dissolve, an accurately-weighed amount of sample in an
accurately-known volume of 0.2 M Tris buffer so that the
solution contains between 2-10-4- 6* 10-4 KNPU/ml and
has a pH of 8.5.
N, B. For each unknown, prepare a sample blank and one or more duplicates (as
necessary).
Keep solutions on ice until ready to assay.
Standard curve
Enzyme standard stock solution: Dissolve accurately-weighed Savinase or Esperase
standard in 100 mil 0.2 M Tris buffer (pH 8.5) to yield l*10-2 KNPU/ml.
Dilute the stock solution as follows:

Tube Stock solution 2 M Tris Fmd volume Activity
buffer stock
En or So 0ml 10 ml 100 ml 0.0*10-4 KNPU/ml
E1 or S1 lml 10 ml 100 ml 1.0*10-4 KNPU/ml
E2 Or S2 2ml 10 ml 100 ml 2.0*10-4 KNPU/ml
E3 or S3 3ml 10ml 100 ml 3.0*10-4 KNPU/ml
E4 or S4 4ml 10 ml 100 ml 4.0*10-4 KNPU/ml
E5 or S5 5ml 10 ml 100 ml 5.0*10-4 KNPU/ml
E6 or S6 6ml 10ml 100 ml 6.0*10-4 KNPU/ml
E = Esperase, S — Savinase

WO 02/18530

PCT/AU01/01094

-20-
APPENDIX III
Durazym®
Unit definition: Durazym Protease Unit (DPU)
The activity is measured relative to a Durazym standard with the same units as the sample i.e. DPU.
A standard curve is prepared using an enzyme, whose activity in DPU is known-Unknowns we then compared to this curve
Buffer: 0.2 M Tris, pH 8.5
Sample activity range: 6*10-4-18*10-4 DPU/ml
Standard blank: 1 ml of 0.2 M Tris buffer pH 8.5 = D0
Substrate: Azocasein solution, 0. 5%, pH 8.5
Sample preparation:
Dissolve an accurately-weighed amount of sample in an
accurately-known volume of 02 M Tris buffer so that the
solution contains between 6*10-4—18*10-4 DPU/ml and
has a pH of 8.5.
NB. For each unknown, prepare a sample blank and one or more duplicates (as
necessary).
Keep solutions on ice until ready to assay.
Standard curve
Enzyme standard stock solution: Dissolve accurately-weighed Durazym standard in
100ml 0.2 M Tris buffer (pH 8.5) to yield l*10-2 DPU/ml

Final volume Activity
Dilute the stock solution as follows: Tube label Stock solution 2 M Tris
buffer stock
D0 0ml 10 ml 100 ml 0.0*10-4 DPU/ml
D1 3ml 10 ml 100 ml 3.0*10-4 DPU/ml
D2 6ml 10 ml 100 ml 6.0*10-4 DPU/ml
D3 9ml 10 ml 100 ml 9.0*10-4 DPU/ml
D4 12 ml 10ml 100 ml 12.0 *10-4 DPU/ml
D3 15 ml 10 ml 100 ml 15.0*10-4 DPU/ml
D6 18 ml 10ml 100 ml 18.0*10-4 DPU/ml

21
WE CLAIM
1. An aqueous composition comprising composition being a surfactant system comprising
an alkyl pyrrolidone and an alkyl polysaccharide in the ratio of 1:37.5 to 75:1 by weight.
2. A composition as claimed in claim 1 wherein the alkyl pyrrolidone is a C8-C18 linear
alkyl pyrrolidone
3. A composition as claimed in claim 1 or 2 wherein the alkyl polysaccharide is an alkyl
polyglucoside ('APG')
4. A composition as claimed in any one of the preceding claims wherein the alkyl
pyrrolidone is n-doecyl pyrrolidone ('n-DP')
5. A composition as claimed in any one of the preceding claims wherein the ratio of alkyl
pyrrolidone to alkyl polysaccharide is between a ratio of 1 part by weight of alkyl
pyrrolidone to 3 parts by weight of alkyl polysaccharide and 3 parts by weight of alkyl
pyrrlidone to 1 part by weight of alkyl polysaccharide.
6. A composition as claimed in any one of the preceding claims wherein the ratio of alkyl
pyrrolidone to alkyl polysaccharide is between a ratio of 1 part by weight of alkyl
pyrrolidone to 3 parts by weight of alkyl polysaccharide and 1 part by weight of alkyl
pyrrolidone to 1 part by weight of alkyl polysaccharide.
7. A composition as claimed in any one of the preceding claims comprising about 1 part by
weight of n-dodecyl pyrrolidone to about 1 part by weight of alkyl polyglucoside.
8. An aqueous composition according to claims 1 to 7 adapted for enhancing the efficacy of
an enzyme containing composition for use in cleaning medical instruments characterised
in that it includes the step of contacting the medical instrument with said composition
alongwith said enzyme composition according to any one of claims 1 to 7.

22
9. A method as claimed in claim 8 wherein composition according to any one of claims 1 to
6 is added to an enzyme containing composition.
10. A method as claimed in claim-9 wherein an alkyl pyrrolidone and an alkyl polysaccharide
are separately added to an enzyme containing composition.
11. A method as claimed in claims 9 or 10 wherein the enzyme containing composition is a
concentrate and the alkyl pyrrolidone and an alkyl polysaccharide are added to the
concentrate prior to its dilution to a working strength.
12. A method as claimed in claim 8 wherein an alkyl pyrrolidone and an alkyl polysaccharide
are each formulated in combination with one or more enzymes to produce a concentrate
suitable for dilution to provide an enzyme defining solution.
13. A method of cleaning a medical instrument including the step of treating the instrument
with a composition according to any one of claims 1 to 7 and at least one enzyme.
14. A method as claimed in claim 13 wherein the alkyl pyrrolidone is a C8-C18 linear alkyl
pyrrolidone.
15. A method as claimed in claims 13 or 14 wherein the alkyl pyrrolidone is n-dodecyl
pyrrolidone ("n-DP")
16. A method as claimed in any one of claims 13 to 15 wherein the alkyl polysaccharide is an
alkyl polyglucoside ("APG").
17. A method as claimed in any one of claims 13 to 16 wherein the ratio of alkyl pyrrolidone
to alkyl polysaccharide is between a ratio of 1 part by weight of alkyl pyrrolidone to 3
parts by weight of alkyl polysaccharide and 3 parts by weight of alkyl pyrrolidone to 1
part by weight of alkyl polysaccharide.

23
18. A method as claimed in any one of claims 13 to 17 wherein the ratio of alkyl pyrrolidone
to alkyl polysaccharide is between a ratio of 1 part by weight of alkyl pyrrolidone to 3
parts by weight of alkyl polysaccharide and 1 part by weight of alkyl pyrrolidone to 1
part by weight of alkyl polysaccharide.
19. A method as claimed in any one of claims 13 to 16 comprising about 1 part by weight of
n-dodecyl pyrrolidone to about 1 part by weight of alkyl polyglucoside.
20. A composition as claimed in anyone of claims 1 to 8 wherein the enzyme is selected from
one or more of proteases, lipases, amylases and cellulases.
21. A composition as claimed in claim 20 wherein further comprising propylene glycol.
22. A composition as claimed in any one of claims 20 to 21 further comprising a nonionic
surfactant.
23. A composition as claimed in any one of claims 20 to 22 wherein APG is present in a
concentration of less man 7.5% w/w.
24. A composition as claimed in claim 20 to 23 wherein n-DP is present in a concentration of
less man 7.5% w/w.
25. A composition as claimed in claim 20 to 24 wherein APG is present in a concentration of
less than 0.3% w/w.
26. A composition as claimed in any one of claims 20 to 25 wherein n-DP is present in a
concentration of less than 0.3% w/w.
27. A composition substantially as herein described with reference to any one of the
examples.

invention relates to an aqueous composition comprising an alkyl pyrrolidone, such as a C8-C18 linear alkyl pyrrolidone, and an alkyl polysaccharide such as an alkyl polyglucoside, and a method of enhancing the efficacy of an enzyme containing composition for use in cleaning medical instruments comprising the step of including in said composition an alkyl pyrrolidone and an alkyl polysaccharide. The methods and compositions of the present invention may further include at least one enzyme such as proteases, hpases amylases and cellulases

Documents:

00260-kolnp-2003 abstract.pdf

00260-kolnp-2003 claims.pdf

00260-kolnp-2003 correspondence.pdf

00260-kolnp-2003 description(complete).pdf

00260-kolnp-2003 drawings.pdf

00260-kolnp-2003 form-1.pdf

00260-kolnp-2003 form-19.pdf

00260-kolnp-2003 form-2.pdf

00260-kolnp-2003 form-3.pdf

00260-kolnp-2003 form-5.pdf

00260-kolnp-2003 pa.pdf

260-KOLNP-2003-FORM-27.pdf

260-kolnp-2003-granted-abstract.pdf

260-kolnp-2003-granted-claims.pdf

260-kolnp-2003-granted-correspondence.pdf

260-kolnp-2003-granted-description (complete).pdf

260-kolnp-2003-granted-drawings.pdf

260-kolnp-2003-granted-examination report.pdf

260-kolnp-2003-granted-form 1.pdf

260-kolnp-2003-granted-form 18.pdf

260-kolnp-2003-granted-form 2.pdf

260-kolnp-2003-granted-form 3.pdf

260-kolnp-2003-granted-form 5.pdf

260-kolnp-2003-granted-letter patent.pdf

260-kolnp-2003-granted-pa.pdf

260-kolnp-2003-granted-reply to examination report.pdf

260-kolnp-2003-granted-specification.pdf


Patent Number 195734
Indian Patent Application Number 260/KOLNP/2003
PG Journal Number 30/2009
Publication Date 24-Jul-2009
Grant Date 30-Dec-2005
Date of Filing 03-Mar-2003
Name of Patentee NOV APHARM RESEARCH (AUSTRALIA) PTY. LTD
Applicant Address 3-11 PRIMOSE AVENUE, ROSEBERY, NSW
Inventors:
# Inventor's Name Inventor's Address
1 KRITZLER,STEVEN 9 REDGUM AVENUE, CRONULLA, NSW 2230
2 SAVA, ALEX 3/124 PADDINGTON STREET,PADDINGTON,NSW 2021
PCT International Classification Number C11D 7/32
PCT International Application Number PCT/AU2001/01094
PCT International Filing date 2001-08-30
PCT Conventions:
# PCT Application Number Date of Convention Priority Country
1 PQ 9844 2000-09-01 Australia